Search the Newsreel

NeOnc Technologies Holdings Inc (NTHI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for NeOnc Technologies Holdings Inc (NTHI). It notes that NTHI has not distributed any dividends over the past five years. The page also includes current stock pricing and market capitalization details for NTHI.

NEON|Neonode Inc|Price:0.991|Chg%:+0.011

This article provides a detailed financial overview and market analysis of Neonode Inc (NEON). It highlights the company's key figures, recent stock performance, and expert insights, noting its healthy fundamentals and significant growth potential despite a recent dip in stock price. The analysis also …

Neonode Inc. Revenue Breakdown – NASDAQ:NEON

Neonode Inc. reported its revenue breakdown for the last fiscal year, reaching $2.10 million USD. The Consumer Electronics segment was the top performer, generating $1.15 million USD. Geographically, Japan contributed the most, accounting for $1.28 million USD of the total revenue.

NeOnc Technologies Holdings Inc (NTHI) Institutional Confidence

This article provides an "Institutional Confidence" score for NeOnc Technologies Holdings Inc (NTHI), which is 3.00, unchanged from its previous score. It details the institutional shareholdings and recent shareholder activity for several entities, including Chen (Thomas C.), AFH Holding & Advisory, L.L.C., and HighPoint …

Neonode Inc (NEON) Institutional Confidence

Neonode Inc (NEON) has an institutional shareholding score of 3.00, placing it 37th out of 60 in the Electronic Equipment & Parts industry. The latest institutional shareholding proportion is 23.68%, a 30.37% increase quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, although …

NEON Q1 2026 Earnings: EPS Misses Estimates Amid Operational Challenges - Strong Earnings Momentum

Neonode Inc|Price:0.770|Chg%:-0.021

Neonode Inc. is a Sweden-based company specializing in advanced optical sensing solutions for contactless touch, touch, and gesture sensing, along with software solutions for scene analysis. The company operates in HMI Solutions, HMI Products, and Remote Sensing Solutions, and its primary revenue source is …

NeOnc Technologies Holdings Inc (NTHI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for NeOnc Technologies Holdings Inc (NTHI), highlighting its current earnings forecast score and industry ranking. Based on analysis from 3 analysts, the stock has a "Buy" rating with a significant upside space for its target price. The article …

NTHI|NeOnc Technologies Holdings Inc|Price:3.420|Chg%:-0.210

NeOnc Technologies Holdings Inc (NTHI) is a clinical-stage biopharmaceutical company focused on treatments for intracranial malignancies, developing lead products NEO100 and NEO212. Analyst ratings suggest a "Buy" with a target price of $16.00, indicating a significant upside, despite the stock's recent weak performance. The …

Japan's Power-Chip Giants Target September Deal to Challenge Infineon

This article first appeared on GuruFocus. Mitsubishi Electric (MIELY), a Japanese company with a power-semiconductor business, is seeking to reach an agreement by September with Toshiba, a diversified Japanese company with chip operations, and Rohm, a Japanese semiconductor supplier, to combine their power-chip businesses. …

NEON stock trades steadily as revenue trends and cash position shape investor view

Neonode Inc. (NEON) shows modest revenue growth of 2% year-over-year, reaching $4.1 million, and has reduced its operating loss to $2.8 million. The company maintains a solid cash position of approximately $8.0 million, supporting operations and product development despite being a micro-cap technology firm. …

Enterprise value to EBITDA forward of NeOnc Technologies Holdings, Inc. – NASDAQ:NTHI

This article provides the enterprise value to EBITDA forward for NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). It appears to be a financial data point from TradingView, indicating a specific metric for the company's valuation. The content itself seems to be a display of this …

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies Holdings, Inc. announced receipt of detailed written feedback from the FDA regarding the chemistry, manufacturing and controls (CMC) development program for its drug NEO212, and the planned transition from a capsule to a tablet formulation. The feedback clarifies requirements for late-stage development, …

NEONC TECHNOLOGIES - TO UPDATE NEO212 DEVELOPMENT PLAN AFTER INCORPORATING FDA FEEDBACK

NEONC Technologies plans to update its NEO212 development plan following feedback from the FDA. This indicates a key regulatory step in advancing their product. The company aims to refine its strategy to align with the FDA's requirements.

Neonc Technologies - Cancels July 9 FDA Meeti

This article provides a brief but critical update regarding Neonc Technologies. The company has announced the cancellation of its previously scheduled FDA meeting on July 9. Further details or implications of this cancellation are not provided in this snippet.

FDA Says NEO212 Drug-Product Plan May Run Alongside Late-Stage Trials

NeOnc Technologies received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) program for its drug, NEO212, which enabled them to cancel their Type B End-of-Phase 1 meeting. The FDA's feedback indicated that the proposed CMC development approach is reasonable …

NeOnc receives FDA CMC feedback on NEO212; capsule-to-tablet bioavailability study advised

NeOnc has received detailed FDA feedback on the Chemistry, Manufacturing, and Controls (CMC) development for NEO212, along with guidance for transitioning from a capsule to a tablet formulation. The FDA found NeOnc's development approach reasonable and recommended an in vivo relative bioavailability study to …

NeOnc Technologies (NASDAQ: NTHI) receives detailed FDA CMC feedback on NEO212

NeOnc Technologies Holdings, Inc. announced it received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) development program for its drug candidate NEO212. The FDA's feedback covers manufacturing, formulation, bioavailability, and the transition from capsule to tablet for late-stage development. …

NeOnc receives FDA feedback on NEO212 manufacturing requirements

NeOnc Technologies Holdings, Inc. received written feedback from the FDA regarding manufacturing requirements for its drug NEO212, streamlining the development process by clarifying chemistry, manufacturing, and controls aspects. Despite recent stock volatility and being near its 52-week low, the FDA's input was deemed sufficiently …

Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off

Insiders at NeOnc Technologies Holdings have purchased US$615.6k worth of shares over the past year at an average price of US$5.51, which has since decreased to US$411.4k due to a 15% stock decline. Despite the loss, recent insider buying, particularly US$138k in the last …

Infineon-Prognose 2027: KI-Boom treibt Aktie auf Rekordhoch

Infineon Aktie: Perspektiven auf Wachstum!

Infineon Prognose: Aktie als DAX Gewinner mit Kurspotenzial bis 55 EUR

Infineon Prognose: Aktie größter DAX Verlierer – Chartanalyse & Ausblick

Infineon Aktie Prognose: Kursziele von Drittanbietern